BASILEA N | 38,200 / -0,39% |
Fecha/Hora | 06.07. / 14:55 |
Dif. / Dif.(%) | -0,150 / -0,39% |
Bid | 38,200 / 50 |
Ask | 38,300 / 74 |
Apertura | 38,900 |
Cierre del día anterior | 38,350 |
Máxima sesión | 39,300 |
Mínima sesión | 38,000 |
Volumen [CHF] | 712.388,800 |
Volumen [Unidades] | 18.510 |
Fijación de precios | 185 |
ISIN | CH0011432447 |
Símbolo | BSLN |
Bolsa | SIX Swiss Exchange |
Tipo | Acciones |
Bolsa | Último | Volumen | |
---|---|---|---|
SIX Swiss Ex.. | 38,200 | ![]() |
18.510 |
Cboe Europe .. | 38,30 | ![]() |
1.070 |
Cboe Europe .. | 38,20 | ![]() |
1.026 |
Turquoise | 38,20 | ![]() |
890 |
London Domes.. | 38,30 | ![]() |
649 |
Lang & Schwa.. | 38,60 | ![]() |
|
Nasdaq Other.. | 41,0000 | 40 | |
München | 32,300 | 0 | |
Berlin | 32,100 | 0 | |
Frankfurt | 32,2800 | 0 | |
gettex | 32,340 | ||
TradeGate | 30,300 | 33 | |
EUREX | Opciones |
Noticias
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire